Study of QL1706 plus HPV vaccine for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (QL1706) and a nine-strain HPV vaccine as a first treatment for cervical cancer that has come back, spread, or persists. It aims to see if this approach can help people with persistent, recurrent, or metastatic cervical cancer who have not had prior systemic therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had previous treatment for cervical cancer that has spread or come back.
- Your cancer is confirmed by a biopsy and can be measured on scans (like CT or MRI).
- You have recovered from side effects of any prior treatments (except hair loss).
- You are in good enough health to be up and about (ECOG score 0 or 1) and expected to live at least 3 months.
- Your blood counts and organ function (liver, kidneys, clotting) are within normal ranges.
- If you can become pregnant, you must have a negative pregnancy test and use effective birth control during and for 90 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This trial tests a new treatment (QL706) combined with chemotherapy, with or without bevacizumab, for cervical cancer that has stopped responding to previous immunotherapy. It aims to find a better option for patients whose disease has progressed after anti-PD-1/PD-L1 therapy.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
Hear when a new Cervical Cancer Stage IVB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.